Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

Rhea-AI Summary

Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company focused on T cell engagers for solid tumors, has announced a poster presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting. The presentation will feature their clinical asset CTIM-76, a Claudin 6 x CD3 bispecific antibody.

The poster, titled 'Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6,' will be presented on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB of the George R. Brown Convention Center in Houston, TX. The authors of the presentation are Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.

Positive

• Poster presentation at a major cancer immunotherapy conference (SITC)
• Showcasing clinical asset CTIM-76, a bispecific antibody for solid tumors

Negative

• None.

PHILADELPHIA, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced a poster regarding the Company’s clinical asset, CTIM-76, a Claudin 6 x CD3 bispecific antibody will be presented at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, being held November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX.

Presentation Details:

Title:	Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6
Authors:	Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, Eric Butz
Abstract Number:	1288
Date and Time:	Saturday, November 9, 2024, 9:00a.m. CDT
Location:	Exhibit Halls AB

For more information and to view the abstract, visit the SITC 39^th Annual Meeting website.

About CTIM-76
CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy.

About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.

Forward-looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain SITC presenters to participate in and present at conferences, (ii) the potential benefits, characteristics, safety and side effect profile of our product candidates, and (iii) the likelihood data will support future development. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.

Investor Relations Contact:
Jennifer Minai-Azary
Chief Financial Officer
Context Therapeutics Inc.
IR@contexttherapeutics.com

FAQ

What is Context Therapeutics presenting at SITC 39th Annual Meeting?

Context Therapeutics is presenting a poster on CTIM-76, their Claudin 6 x CD3 bispecific antibody, titled 'Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6'.

When and where is Context Therapeutics (CNTX) presenting at SITC 2024?

Context Therapeutics is presenting on Saturday, November 9, 2024, at 9:00 a.m. CDT in Exhibit Halls AB of the George R. Brown Convention Center in Houston, TX.

Who are the authors of Context Therapeutics' SITC 2024 poster presentation?

The authors of the poster presentation are Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.

What is the focus of Context Therapeutics' (CNTX) clinical asset CTIM-76?

CTIM-76 is a Claudin 6 x CD3 bispecific antibody, which is a T cell-redirecting therapy targeting solid tumors.